The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Miners Jump On Upbeat Chinese Data

Mon, 02nd Jun 2014 10:39

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.
-------
FTSE 100 - WINNERS
-------
Anglo American, up 1.9%, Rio Tinto, up 1.7%, Glencore, up 1.4%, BHP Billiton, up 0.8%. The mining stocks are all big gainers after a gauge of China's factory activity rose to a five-month high in May, suggesting the world's second-largest economy is stabilizing after a subdued start to the year. The official purchasing managers' index improved to 50.8, from 50.4 in April, its third straight month of improvement.

Shire, up 1.3%. The pharmaceutical company has secured a USD5 billion credit facility from banks including Citigroup to finance a takeover offer for the US's NPS Pharmaceuticals, The Times said on Monday, citing insiders. It is believed to have arranged the deal to buttress its takeover offer for NPS, a developer of drugs for sufferers of a debilitating bowel condition.
-------
FTSE 100 - LOSERS
-------
Standard Life, down 2.6%. The long-term savings and investments provider is the biggest faller in the blue-chip index following reports in the weekend press that the pension industry will see a further shake up during the Queen's Speech on Wednesday. "It is thought that the Queen's Speech on Wednesday will include news that UK workers will be offered 'collective pension schemes' by 2016, delivering efficiency for the saver, but which would evidently prove less lucrative for providers at a time when opaque financial charging structures are under the microscope," says Michael van Dulken, head of research at Accendo Markets.

Smith & Nephew, down 1.8%. The medical technology company has fallen sharply following a strong share price run, which saw it close the last three trading sessions as the FTSE 100's biggest riser. The group jumped 9.8% in three days after the Financial Times published an article on Wednesday that suggested that Stryker, a US maker of hip implants and knee replacements, was about to make an unquantified takeover bid for the company. While Stryker quickly denied the rumours, Smith & Nephew's shares still benefited from the speculation.

GlaxoSmithKline, down 0.5%. UK-based biotechnology company Adaptimmune Ltd has confirmed that it has entered into a collaboration and licensing agreement with pharmaceutical giant GlaxoSmithKline worth a potential USD350 million over the next seven years, for its cancer programme. Under the agreement, the two companies will develop and commercialise Adaptimmune's NY-ESO-1 cancer treatment, as well as Adaptimmune's other treatments using its T-cell receptor engineering technology. Separately, on Sunday, Glaxo announced that a late stage study of its two anti-HER2 agents lapatinib and trastuzumab did not meet their primary endpoint of improved disease free survival compared to a treatment of just trastuzumab for HER2 positive early breast cancer.
-------
FTSE 250 - WINNERS
-------
St Modwen Properties, up 2.7%. The property company said it still expects to report pretax profit for the first half of its financial year significantly up on the year-earlier period, after it continued to perform "strongly" over the past two months. It said it expects its asset management and added value activities to be reflected positively in half-year valuations, while initial indications point to a rise in market valuations for the first half of the year compared with November 2013, reflecting improvements in the residential and commercial property markets across the UK.

Man Group, up 2.5%. Berenberg has upgraded the hedge fund manager to Hold, from Sell, increasing its target price to 90.00 pence, from 70.00p. After an enormous restructuring effort over the last three years, Man Group looks to be turning a corner as legacy issues associated with its quantitative fund management arm, AHL, are set to gradually ease, said Berenberg analyst Pras Jeyanandhan.
-------
FTSE 250 - LOSERS
-------
Fenner, down 2.8%. The polymer products maker's shares are among the biggest fallers in the mid-cap index for a second day in a row, having dropped 10% on Friday, after it said on Friday that its underlying pretax profit for the current financial year will come in 10% to 15% below the consensus estimate of GBP77.6 million. Liberum Capital has cut its target price on the company to 345.00 pence from 445.00p Monday, following the warning.
-------
AIM ALL-SHARE - WINNERS
-------
Bglobal, up 60%. The company said it had agreed to sell its Utiligroup Ltd subsidiary for GBP16.1 million in cash to private equity company NorthEdge Capital LLP, and plans to return money to shareholders and de-list from AIM once the deal completes. Bglobal said the deal will have to be approved by its shareholders. It said it expects to have cash balances of GBP16.8 million after the deal completes, and is already talking with its advisors about the most effective way of returning this money to its shareholders.

Union Jack Oil, up 42%. The oil and gas exploration and development company said that an independent technical report carried out on its PEDL201 licence in the UK Midlands has confirmed significant shale oil and gas potential at the Widmerpool Gulf region of the site. It said the report has shown mean gross unrisked estimates of 5.4 billion barrels of oil and over 2.7 trillion standard cubic feet of gas in the region.

Leni Gas & Oil, up 30%. The oil and gas exploration and development company said its GY-664 well in the Goudron Field, Trinidad, was brought into production on Friday and has now stabilised at a strong rate of 240 barrels of oil per day, while drilling at its GY-665 well has already found a region of oil-bearing sand. The GY-664 well has achieved a stabilised rate four-times above production assumptions of 60 barrels of oil per day based on historical data from the field. The group also announced that its second development well at the site, GY-665, has now drilled to 1,606 feet on its way to a total depth of 3,500 feet, and it has already intersected a 310 feet region of gross oil sand in the Goudron sandstones formation of the site.

Range Resources, up 23%. The hydrocarbon exploration firm said it has entered into a services agreement with LandOcean Energy Services Co Ltd, coupled with a financing package of USD50 million. It said that as part of a master services agreement, LandOcean will be the preferred services contractor for Range's oilfield services, including geoscience, engineering, procurement and construction. The company said services provided under the deal will be agreed on an individual basis and where services have led to increased production, LandOcean will be entitled to an incremental production bonus share of its costs and capital expenditure. It said the deal will last eight years and could cover a total contract value of up to USD400 million. Range Resources also said that in addition to the agreement, LandOcean will provide the company with an option to take up to USD50 million in financing, primarily for LandOcean's services.

Tanfield Group, up 7.7%. The investment company said it swung to a pretax profit in 2013 due to positive adjustments in the fair value of its investments, and it outlined a new investment strategy and detailed plans to raise money to acquire and fund new investments in the technology sector. It said it made a GBP7.4 million pretax profit in 2013, compared with a GBP13.4 million pretax loss in 2012. Revenue fell to GBP2.2 million, from GBP3.3 million, while staff costs and other operating expenses fell to GBP3.3 million, from GBP4.6 million.

Scancell Holdings, up 6.5%. The cancer treatment developer said the latest results from a trial of its SCIB1 ImmunoBodyÒ treatment on skin cancer had shown further evidence of tumour reduction and disease control, enhanced immune responses and "highly encouraging" survival times. It said the latest result from the continuing phase 1/2 clinical trial in patients with Stage III/IV melanoma also showed that SCIB1 is safe and well-tolerated.
-------
AIM ALL-SHARE - LOSERS
-------
DQ Entertainment, off 27%. The animation, gaming, live action, and entertainment production and distribution company reported higher profit for its last financial year as revenue was lifted by distribution deals as the company tapped new markets in Latin America, Africa, South East Asia and the Middle East. However, the company also reported provisions for bad debts, a smaller order book, and said it won't pay a dividend due to its negative cash position.
-------
By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2023 14:27

Scancell appoints healthcare finance veteran as new CFO

(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.

Read more
29 Aug 2023 09:53

IN BRIEF: Scancell appoints Prenetics' Sath Nirmalananthan as new CFO

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Hires Sath Nirmalananthan to be chief financial officer, starting immediately. Nirmalananthan previously was CFO for Europe, Middle East & Africa at Prenetics Ltd, a genomics-driven health sciences company. His appointment at Scancell follows Keith Green's retirement as director of finance.

Read more
31 Jul 2023 10:46

AIM WINNERS & LOSERS: Aptamer reshuffles board; Scancell expands trial

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Jul 2023 10:23

Scancell shares jump on trial expansion for Modi-1 vaccine

(Alliance News) - Scancell Holdings PLC on Monday said it has expanded its Modi-1 trial for the use of checkpoint inhibitors on cancer patients.

Read more
10 Jul 2023 11:45

IN BRIEF: Scancell to focus on cancer vaccine assets amid trial data

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Will focus on lead cancer vaccine assets SCIB1 and Modi-1 following encouraging data from clinical trials. Adds phase two single arm scope trial investigating the safety and tolerability of using SCIB1 in combination with checkpoint inhibitors in patients with advanced melanoma is progressing well and notes a potential pathway for a registration trial. Adds it is fully funded to the second half of 2024 due to its increasing focus on the two clinical assets.

Read more
2 Jun 2023 13:18

Scancell to present positive recent findings at oncology summit

(Sharecast News) - Immunotherapy developer Scancell said on Friday that it is set to present an informative poster at the American Society of Clinical Oncology Meeting (ASCO) 2023 annual meeting in Chicago from 2 to 6 June.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
21 Feb 2023 12:14

Scancell shares jump on positive cancer vaccine progress

(Sharecast News) - Immunotherapy developer Scancell announced the completion of the monotherapy dose-finding arm of the phase 1 and 2 'ModiFY' clinical trial on Tuesday.

Read more
21 Feb 2023 11:56

Scancell shares up on encouraging data from ModiFY cancer trial

(Alliance News) - Scancell Holdings PLC on Tuesday said that it has completed the monotherapy dose finding arm of its multicentre Phase 1/2 ModiFY clinical trial, designed to treat cancer patients.

Read more
13 Feb 2023 11:38

Scancell gets positive result from needle-free Covid vaccines trial

(Alliance News) - Scancell Holdings PLC on Monday reported a positive response in its 'Covidity' trial, which aims to deliver needle-free injectable Covid vaccines.

Read more
1 Feb 2023 21:41

TRADING UPDATES: PetroNeft extends maturity; NetScientific loses chair

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
25 Jan 2023 14:43

TRADING UPDATES: Van Elle and Hargreaves Services post profit rises

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
18 Jan 2023 15:50

UK earnings, trading statements calendar - next 7 days

Thursday 19 January 
AJ Bell PLCTrading Statement
Bakkavor Group PLCTrading Statement
BHP Group LtdTrading Statement
boohoo Group PLCTrading Statement
Centamin PLCTrading Statement
Deliveroo PLCTrading Statement
Dunelm Group PLCTrading Statement
Energean PLCTrading Statement
Frontier Developments PLCHalf Year Results
Harbour Energy PLCTrading Statement
Headlam Group PLCTrading Statement
Ilika PLCHalf Year Results
Kier Group PLCTrading Statement
Luceco PLCTrading Statement
Network International Holdings PLCTrading Statement
Premier Foods PLCTrading Statement
Sage Group PLCTrading Statement
Zotefoams PLCTrading Statement
Friday 20 January 
4imprint Group PLCTrading Statement
Close Brothers Group PLCTrading Statement
Goldplat PLCFull Year Results
Ninety One PLCTrading Statement
Workspace Group PLCTrading Statement
PensionBee Group PLCTrading Statement
TheWorks.co.uk PLCHalf Year Results
Monday 23 January 
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Tuesday 24 January 
Accrol Group Holdings PLCHalf Year Results
Associated British Foods PLCTrading Statement
Henry Boot PLCTrading Statement
Oxford BioDynamics PLCFull Year Results
Saga PLCTrading Statement
Staffline Group PLCTrading Statement
Sureserve Group PLCFull Year Results
Velocity Composites PLCFull Year Results
Wednesday 25 January 
CMC Markets PLCTrading Statement
Conduit Holdings LtdTrading Statement
easyJet PLCTrading Statement
Forterra PLCTrading Statement
Hargreaves Services PLCHalf Year Results
hVIVO PLCTrading Statement
JD Wetherspoon PLCTrading Statement
Keywords Studios PLCTrading Statement
Quilter PLCTrading Statement
Scancell Holdings PLCHalf Year Results
Tullow Oil PLCTrading Statement
Van Elle Holdings PLCHalf Year Results
Watkin Jones PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
7 Nov 2022 12:56

Scancell in-licences SNAPvax technology for its Modi-2 cancer treatment

(Alliance News) - Scancell Holdings PLC on Monday said it has in-licensed SNAPvax technology from Vaccitech PLC to help develop its cancer treatments.

Read more
7 Nov 2022 09:29

Scancell licenses Vaccitech IP for its next vaccine candidate

(Sharecast News) - Scancell has in-licensed 'SNAPvax' technology from clinical-stage biopharmaceutical company Vaccitech, it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.